Cardiosolutions, Inc. was incorporated in Delaware in 2006 to develop a less invasive, percutaneous alternative to open 
heart surgical repair of the mitral valve. Cardiosolutions’ pioneering technology, the Percu-Pro System, is designed to greatly reduce the degree of mitral regurgitation in patients with either functional or degenerative valve insufficiency. Current treatment methods involve a sternotomy or cutting open the chest and separating the ribs at the breastbone, an invasive, time consuming and costly procedure.
Cardiosolutions believes the Percu-Pro System will address the condition of mitral regurgitation percutaneously, by delivering an implant that will provide a sealing surface for the leaflets of the mitral valve. The delivery of the implant will be via catheter inserted through a small puncture in the patient’s leg. The procedure will enable the interventionalist to provide a cost efficient, less traumatic and user friendly substitute for the standard modality to a much wider patient base. The Company’s target market is made up of patients of all ages suffering moderate to severe mitral regurgitation including a portion of those now in congestive heart failure.